test

Developmental Therapeutics

Recent Publications

Seagle BL, Dawson M, Samuelson R, Chacho MS, Rutherford TJ, Shahabi S. 
Reprod Sci. 2014 Dec 7.

Menderes G, Azodi M, Schwartz P, Silasi DA.
Comparison of Lymphedema Incidence Between 2 Lymphadenectomy Techniques in Patients With Uterine Cancer Undergoing Robotic Staging.
Int J Gynecol Cancer. 2014 Nov 10.

Kenney PA, Vikram R, Prasad SR, Tamboli P, Matin SF, Wood CG, Karam JA.
Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney: A Retrospective Detailed Study of Radiologic, Pathologic and Clinical Outcomes.
BJU Int. 2014 Nov 14.

Sumi NJ, Lima E, Pizzonia J, Orton SP, Craveiro V, Joo W, Holmberg JC, Gurrea M, Yang-Hartwich Y, Alvero A, Mor G.
Murine Model for Non-invasive Imaging to Detect and Monitor OvarianCancerRecurrence.
J Vis Exp. 2014 Nov 2;(93).

Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, Saltzman WM, Slack FJ.
MicroRNA silencing forcancertherapy targeted to the tumour microenvironment.
Nature. 2014 Nov 17.

Wu J, Ng J, Christos PJ, Goldenberg AS, Sparano J, Sung MW, Hochster HS, Muggia FM.
Chronic Thalidomide and Chemoembolization for Hepatocellular Carcinoma.
Oncologist. 2014 Oct 31.

Menderes G, Azodi M, Schwartz P, Silasi DA.
Comparison of Lymphedema Incidence Between 2 Lymphadenectomy Techniques in Patients With Uterine Cancer Undergoing Robotic Staging.
Int J Gynecol Cancer. 2014 Nov 10.

Barr ML, Jilaveanu LB, Camp RL, Adeniran AJ, Kluger HM, Shuch B.
PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma?
J Clin Pathol. 2014 Oct 14.

Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM.
PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.
Clin Cancer Res. 2014 Oct 14.

Hochster HS, Uboha N, Messersmith W, Gold PJ, ONeil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L.
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
Cancer Chemother Pharmacol. 2014 Oct 17.

Henick BS, Herbst RS, Goldberg SB.
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer.
Expert Opin Ther Targets. 2014 Oct 21:1-14.

Vincent T. DeVita Jr, Alexander M. M. Eggermont, Samuel Hellman & David J. Kerr
Clinical cancer research: the past, present and the future
Nature Reviews Clinical Oncology 11,663-669(2014).

Kris MG, Arenberg DA, Herbst RS, Riely GJ.
Emerging Science and Therapies in Non-small-Cell Lung Cancer: Targeting the MET Pathway.
Clin Lung Cancer. 2014 Nov;15(6):475.

Yang-Hartwich Y, Romanoff E, Bingham J, Alvero AB, Mor G.
Detection of p53 Protein Transcriptional Activity by Chromatin Immunoprecipitation.
Methods Mol Biol. 2015;1219:87-93.

Lott JP, Wititsuwannakul J, Lee JJ, Ariyan S, Narayan D, Kluger HH, Lazova R.
Clinical characteristics associated with Spitz nevi and Spitzoid malignant melanomas: The YaleUniversity Spitzoid Neoplasm Repository experience, 1991 to 2008.
J Am Acad Dermatol. 2014 Oct 9.

Barr ML, Jilaveanu LB, Camp RL, Adeniran AJ, Kluger HM, Shuch B.
PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma?
J Clin Pathol. 2014 Oct 14.

Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM.
PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.
Clin Cancer Res. 2014 Oct 14.

Li J, Yao X, Kortmansky JS, Fischbach NA, Stein S, Deng Y, Zhang Y, Doddamane I, Karimeddini D, Hochster HS, Lacy J.
Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma.
Am J Clin Oncol. 2014 Aug 20.

Neubauer P, Cañadas K, Sasaki CT.
Delayed platysma myocutaneous turnover flap for repair of pharyngocutaneous fistula.
Am J Otolaryngol. 2014 Sep 3.

DeVita VT Jr, Eggermont AM, Hellman S, Kerr DJ.
Clinical cancer research: the past, present and the future.
Nat Rev Clin Oncol. 2014 Sep 23.

Lilly E, Burke M, Kluger H, Choi J.
Pregabalin for the Treatment of Painful Hand-Foot Skin Reaction Associated With Dabrafenib.
JAMA Dermatol. 2014 Sep 24.

English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
Cancer. 2014 Sep 23.

Yang-Hartwich Y, Soteras MG, Lin ZP, Holmberg J, Sumi N, Craveiro V, Liang M, Romanoff E, Bingham J, Garofalo F, Alvero A, Mor G.
p53 protein aggregation promotes platinum resistance in ovarian cancer.
Oncogene. 2014 Sep 29.

Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrialcancer in vitro and in vivo.
Br J Cancer. 2014 Sep 30.

Jürgensmeier JM, Eder JP, Herbst RS.
New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.
Clin Cancer Res. 2014 Sep 1;20(17):4425-35

Politi K, Gettinger S.
Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer.
Clin Cancer Res. 2014 Sep 16.

Jürgensmeier JM, Eder JP, Herbst RS.
New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.
Clin Cancer Res. 2014 Sep 1;20(17):4425-35

Ediriwickrema A, Zhou J, Deng Y, Saltzman WM.
Multi-layered nanoparticles for combination gene and drug delivery to tumors.
Biomaterials. 2014 Aug 8.

Lynch TJ Jr, Spigel DR, Brahmer J, Fischbach N, Garst J, Jahanzeb M, Kumar P, Vidaver RM, Wozniak AJ, Fish S, Flick ED, Leon L, Hazard SJ, Kosty MP; ARIES Study Investigators.
Safety and Effectiveness of Bevacizumab-Containing Treatment for Non-Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study.
J Thorac Oncol. 2014 Sep;9(9):1332-9.

Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, Nicoletti R, Rutherford TJ, Schwartz PE, Santin AD.
Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Gynecol Oncol. 2014 Aug 12.

Kumar VP, Cisneros JA, Frey KM, Castellanos-Gonzalez A, Wang Y, Gangjee A, White AC Jr, Jorgensen WL, Anderson KS.
Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase.
Bioorg Med Chem Lett. 2014 Jul 24.

Nicholson AD, Guo X, Sullivan CA, Cha CH.
Automated Quantitative Analysis of Tissue Microarray of 443 Patients with Colorectal Adenocarcinoma: Low Expression of Bcl-2 Predicts Poor Survival.
J Am Coll Surg. 2014 Jul 16.

Ishiguro K, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Zhu YL, Sartorelli AC, Rutherford TJ, Ratner ES.
Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.
Biochem Pharmacol. 2014 Aug 14.

Yang-Hartwich Y, Gurrea-Soteras M, Sumi N, Joo WD, Holmberg JC, Craveiro V, Alvero AB, Mor G.
Ovulation and extra-ovarian origin of ovarian cancer.
Sci Rep. 2014 Aug 19;4:6116.

Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W.
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations.
Cancer Discov. 2014 Jul 29.

Fadel TR, Sharp FA, Vudattu N, Ragheb R, Garyu J, Kim D, Hong E, Li N, Haller GL, Pfefferle LD, Justesen S, Harold KC, Fahmy TM.
A carbon nanotube-polymer composite for T-cell therapy.

Choi JN.
Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab.
Semin Cutan Med Surg. 2014 Mar;33(1):40-8.

Woo CM, Ranjan N, Arya DP, Herzon SB.
Analysis of Diazofluorene DNA Binding and Damaging Activity: DNA Cleavage by a Synthetic Monomeric Diazofluorene.
Angew Chem Int Ed Engl. 2014 Jul 9

Grant R, Kolb L, Moliterno J.
Molecular and genetic pathways in gliomas: the future of personalized therapeutics.
CNS Oncol. 2014 Mar;3(2):123-136.

Zhang B, Bolognia J, Marks P, Podoltsev N.
Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia.
Cancer Chemother Pharmacol.

Pasternak MC, Black JD, Azodi M, Gariepy A.
An unexpected mass of the urachus: A Case Report.
Am J Obstet Gynecol. 2014 Jun 6.

Menderes G, Azodi M, Clark L, Xu X, Lu L, Ratner E, Schwartz PE, Rutherford TJ, Santin AD, Silasi DA.
Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging.
Int J Gynecol Cancer. 2014 Jun 12.

Shuch B, Amin A, Armstrong AJ, Eble JN, Ficarra V, Lopez-Beltran A, Martignoni G, Rini BI, Kutikov A.
Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity.
Eur Urol. 2014 May 20.

Cheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL.
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.
BMC Cancer. 2014 May 8;14(1):326.

English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.
T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
Cancer Med. 2014 Jun 2.

Vasan N, Boyer J, Herbst RS.
A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non-Small Cell Lung Cancer.
Clin Cancer Res. 2014 Jun 3.

Valentina Pirazzoli, Caroline Nebhan, Xiaoling Song, Anna Wurtz, Zenta Walther, Guoping Cai, Zhongming Zhao, Peilin Jia, Elisa de Stanchina, Erik M. Shapiro, Molly Gale, Ruonan Yin, Leora Horn, David Carbone, Philip J Stephens, Vincent Miller, Scott Gettinger, William Pao and Katerina Politi
Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1
j.celrep.2014.04.014

Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K.
Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1.
Cell Rep. 2014 May 7.

Agochukwu N, Shuch B.
Clinical management of renal cell carcinoma with venous tumor thrombus.
World J Urol. 2014 Apr 22.

Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, Kluger H, Tejwani S, Green J, Ramakrishna V, Crocker A, Vitale L, Yellin M, Davis T, Keler T.
Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205.
Sci Transl Med. 2014 Apr 16;6(232):232ra51.

Brose MS, Frenette CT, Keefe SM, Stein SM.
Management of Sorafenib-Related Adverse Events: A Clinician's Perspective.
Semin Oncol. 2014 Feb;41 Suppl 2:S1-S16.

Shi X, Liu J, Huang J, Zhou Y, Xie Y, Ma S.
A penalized robust method for identifying gene-environment interactions.
Genet Epidemiol. 2014 Apr;38(3):220-30.

Fadel TR, Fahmy TM.
Immunotherapy applications of carbon nanotubes: from design to safe applications.
Trends Biotechnol. 2014 Mar 11.

Muftuoglu Y, Sohl CD, Mislak AC, Mitsuya H, Sarafianos SG, Anderson KS.
Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kinetics.
Antiviral Res. 2014 Mar 12.

Neumeister VM, Parisi F, England AM, Siddiqui S, Anagnostou V, Zarrella E, Vassilakopolou M, Bai Y, Saylor S, Sapino A, Kluger Y, Hicks DG, Bussolati G, Kwei S, Rimm DL.
A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue.
Lab Invest. 2014 Feb 17.

de Bruin EC, Cowell CF, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger SN, Walther Z, Wurtz A, Heynen GJ, Heideman DA, Gomez-Roman JJ, García-Castaño A, Gong Y, Ladanyi M, Varmus H, Bernards R, Smit EF, Politi K, Downward J.
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.
Cancer Discov. 2014 Feb 17.

Onn A, Bar J, Herbst RS.
Angiogenesis inhibition and lung-cancer therapy.
Lancet Oncol. 2014 Feb;15(2):124-5.

Li J, Huang Y, Zhang BN, Fan JH, Huang R, Zhang P, Wang SL, Zheng S, Zhang B, Yang HJ, Xie XM, Tang ZH, Li H, He JJ, Hsieh E, Qiao YL, Li JY.
Body mass index and breast cancer defined by biological receptor status in pre-menopausal and post-menopausal women: a multicenter study in china.
PLoS One. 2014 Jan 29;9(1):e87224.

Sznol M.
Expanded use trials-are there better approaches to minimize adverse consequences to the clinical trials program?
Cancer J. 2014 Jan-Feb;20(1):25-6.

Aziz SA, Sznol JA, Albiges L, Zito C, Jilaveanu LB, Camp RL, Escudier B, Kluger HM.
Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma.
Cancer Cell Int. 2014 Jan 14;14(1):4.

Gibson J, Lacy J, Matloff E, Robert M.
Microsatellite instability testing in colorectal carcinoma: a practical guide.
Clin Gastroenterol Hepatol. 2014 Feb;12(2):171-176.e1.

Toll BA, Rojewski AM, Duncan LR, Latimer-Cheung AE, Fucito LM, Boyer JL, O'Malley SS, Salovey P, Herbst RS.
Quitting smoking will benefit your health": the evolution of clinician messaging to encourage tobacco cessation.
Clin Cancer Res. 2014 Jan 15;20(2):301-9

Brown C, Chen C, Cha C.
Gastrohepatic Fistula as a Complication of Laparoscopic Radiofrequency Liver Ablation in a Patient With Intrahepatic Cholangiocarcinoma.
J Clin Gastroenterol. 2014 Jan 16.

Sznol M.
Expanded use trials-are there better approaches to minimize adverse consequences to the clinical trials program?
Cancer J. 2014 Jan-Feb;20(1):25-6.

Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, Metwalli AR, Srinivasan R, Linehan WM.
Defining Early-Onset Kidney Cancer: Implications for Germline and Somatic Mutation Testing and Clinical Management.
J Clin Oncol. 2013 Dec 30.

Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT.
Treatment of hodgkin lymphoma: a 50-year perspective.
J Clin Oncol. 2014 Jan 20;32(3):163-8. doi: 10.1200/JCO.2013.53.1194.

Malkhasyan K, Deshpande HA, Adeniran AJ, Colberg JW, Petrylak DP.
The use of serum hCG as a marker of tumor progression and of the response of metastatic urothelial cancer to systemic chemotherapy.
Oncology (Williston Park). 2013 Oct;27(10):1028, 1030.

Chang B, Sokhn J, James E, Abu-Khalaf M.
Prolonged Progression-Free Survival in a Patient With Triple-Negative Breast Cancer Metastatic to the Liver After Chemotherapy and Local Radiation Therapy.
Clin Breast Cancer. 2013 Nov 21.

Schutt CA, Neubauer P, Paskhover B, Fang-Yong L, Sasaki CT.
The Impact of Dairy Consumption on Salivary Inoculum.
Dysphagia. 2014 Jan 3.

Balogh EP, Dresler C, Fleury ME, Gritz ER, Kean TJ, Myers ML, Nass SJ, Nevidjon B, Toll BA, Warren GW, Herbst RS.
Reducing Tobacco-Related Cancer Incidence and Mortality: Summary of an Institute of Medicine Workshop.
Oncologist. 2013 Dec 4.

Stein SM, Tiersten A, Hochster HS, Blank SV, Pothuri B, Curtin J, Shapira I, Levinson B, Ivy P, Joseph B, Guddati AK, Muggia F.
A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.
Int J Gynecol Cancer. 2013 Nov;23(9):1577-82.

Joo WD, Visintin I, Mor G.
Targeted cancer therapy - Are the days of systemic chemotherapy numbered?
Maturitas. 2013 Sep 20.

Abu-Khalf M, Pusztai L.
Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer.
Breast. 2013 Aug;22 Suppl 2:S83-7.

Patel TR, Chiang VL.
Secondary Neoplasms after Stereotactic Radiosurgery.
World Neurosurg. 2013 Oct 19.

English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz PE, Rutherford T, Santin AD.
HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
Gynecol Oncol. 2013 Sep 4.

Dubrow R, Darefsky AS, Jacobs DI, Park LS, Rose MG, Laurans MS, King JT Jr.
Time trends in glioblastoma multiforme survival: the role of temozolomide.
Neuro Oncol. 2013 Sep 17.

Sznol M, Chen L.
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer--Response.
Clin Cancer Res. 2013 Sep 18.

Doddamane I, Butler R, Jhaveri A, Chung GG, Cheng D.
Where does radioimmunotherapy fit in the management of breast cancer?
Immunotherapy. 2013 Aug;5(8):895-904.

Lazova R, Laberge GS, Duvall E, Spoelstra N, Klump V, Sznol M, Cooper D, Spritz RA, Chang JT, Pawelek JM.
A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer.
PLoS One. 2013 Jun 26;8(6):e66731

English DP, Bellone S, Cocco E, Bortolomai I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, Rutherford T, Santin AD.
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
Am J Obstet Gynecol. 2013 Jul 24.

Johung KL, Yao X, Li F, Yu JB, Gettinger SN, Goldberg S, Decker RH, Hess JA, Chiang VL, Contessa JN.
A Clinical Model for Identifying Radiosensitive Tumor Genotypesin Non-Small Cell Lung Cancer.
Clin Cancer Res. 2013 Jul 29.

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M.
Nivolumab plus Ipilimumab in Advanced Melanoma.
N Engl J Med. 2013 Jun 2.

Stein SM.
Hepatocellular carcinoma: perspective of an oncologist.
J Clin Gastroenterol. 2013 Jul;47 Suppl:S47-9.

Velcheti V, Schalper K, Yao X, Cheng H, Kocoglu M, Dhodapkar K, Deng Y, Gettinger S, Rimm DL.
High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas.
PLoS One. 2013 Apr 19;8(4):e61427.

Mitchell KA, Kluger H, Sznol M, Hartman DJ.
Ipilimumab-induced Perforating Colitis.
J Clin Gastroenterol. 2013 Apr 29.

Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD.
Class III β-Tubulin Overexpression in Ovarian Clear Cell and Serous Carcinoma as a Marker for Poor Overall Survival after Platinum/Taxane Chemotherapy and Sensitivity to Patupilone.
Am J Obstet Gynecol. 2013 Apr 10.

Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD.
Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
Cancer. 2013 Apr 12. doi: 10.1002/cncr.28017.

Shumaster V, Bae JW, Gettinger SN, Cai G, Kim AW.
Late recurrence of basaloid carcinoma initially treated as a small cell lung cancer.
J Thorac Dis. 2013 Apr;5(2):E68-70.

Flanigan JC, Jilaveanu LB, Chiang VL, Kluger HM.
Advances in therapy for melanoma brain metastases.
Clin Dermatol. 2013 May-Jun;31(3):264-81.

Hochster HS.
HORIZON I: Is there a future for oral anti-angiogenics on the horizon of colorectal cancer therapy?
Br J Cancer. 2013 Feb 19;108(3):477-8.

Sznol M, Chen L.
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer.
Clin Cancer Res. 2013 Mar 1;19(5):1021-34.

Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS.
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.
Cancer Res. 2013 Jan 15;73(2):571-82.

Aziz SA, Sznol JA, Adeniran A, Parisi F, Kluger Y, Camp RL, Kluger HM.
Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.
BMC Clin Pathol. 2013 Feb 1;13(1):3.

Zhu R, Baumann RP, Patridge E, Penketh PG, Shyam K, Ishiguro K, Sartorelli AC.
Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells.
Bioorg Med Chem Lett. 2013 Jan 11.

Hochster HS.
HORIZON I: Is there a future for oral anti-angiogenics on the horizon of colorectal cancer therapy?
Br J Cancer. 2013 Feb 19;108(3):477-8.

Zhu R, Baumann RP, Patridge E, Penketh PG, Shyam K, Ishiguro K, Sartorelli AC.
Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells.

Bioorg Med Chem Lett. 2013 Jan 11

Zhu R, Baumann RP, Penketh PG, Shyam K, Sartorelli AC.
Hypoxia-Selective O(6)-Alkylguanine-DNA Alkyltransferase Inhibitors: Design, Synthesis, and Evaluation of 6-(Benzyloxy)-2-(aryldiazenyl)-9H-purines as Prodrugs of O(6)-Benzylguanine.
J Med Chem. 2013 Jan 23.

Chefetz I, Alvero AB, Holmberg JC, Lebowitz N, Craveiro V, Yang-Hartwich Y, Yin G, Squillace L, Gurrea Soteras M, Aldo P, Mor G.
TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence.
Cell Cycle. 2013 Jan 16;12(3).

Isobe T, Onn A, Morgensztern D, Jacoby JJ, Wu W, Shintani T, Itasaka S, Shibuya K, Koo PJ, O'Reilly MS, Herbst RS.
Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.
J Thorac Oncol. 2013 Feb;8(2):140-6.

Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
Proc Natl Acad Sci U S A. 2013 Jan 28.

Devita VT Jr.
Research: The moving parts.
CA CancerJ Clin. 2012 Dec 18.

Sznol JA, Jilaveanu LB, Kluger HM.
Studies of NVP-BEZ235 in Melanoma.
Curr Cancer Drug Targets. 2012 Nov 21.

Deshpande HA, Sheth K, Sosa JA, Roman S.
Efficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer.
Clin Med Insights Oncol. 2012;6:355-62.

Lamb KL, Liu Y, Ishiguro K, Kwon Y, Paquet N, Sartorelli AC, Sung P, Rockwell S, Sweasy JB.
Tumor-associated mutations in O(6) -methylguanine DNA-methyltransferase (MGMT) reduce DNA repair functionality.
Mol Carcinog. 2012 Oct 12.

Woo CM, Gholap SL, Lu L, Kaneko M, Li Z, Ravikumar PC, Herzon SB.
Development of enantioselective synthetic routes to (-)-kinamycin f and (-)-lomaiviticin aglycon.
J Am Chem Soc. 2012 Oct 17;134(41):17262-73.

Lamb KL, Liu Y, Ishiguro K, Kwon Y, Paquet N, Sartorelli AC, Sung P, Rockwell S, Sweasy JB.
Tumor-associated mutations in O(6) -methylguanine DNA-methyltransferase (MGMT) reduce DNA repair functionality.
Mol Carcinog. 2012 Oct 12.

Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P.
Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer.
J Clin Oncol. 2012 Sep 17.

Morgensztern D, Waqar S, Subramanian J, Gao F, Trinkaus K, Govindan R.
Prognostic Significance of Tumor Size in Patients with Stage III Non-Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey from 1998 to 2003.
J Thorac Oncol. 2012 Oct;7(10):1479-84.

Morgensztern D, Waqar S, Subramanian J, Trinkaus K, Govindan R.
Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
J Thorac Oncol. 2012 Oct;7(10):1485-9.

Woo CM, Gholap SL, Lu L, Kaneko M, Li Z, Ravikumar PC, Herzon SB.
Development of Enantioselective Synthetic Routes to (-)-Kinamycin F and (-)-Lomaiviticin Aglycon.
J Am Chem Soc. 2012 Oct 3.

Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV.
A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2012 Aug 8.

Barrera FN, Fendos J, Engelman DM.
Membrane physical properties influence transmembrane helix formation.
Proc Natl Acad Sci U S A. 2012 Aug 20.

Virk RK, Van Dyke AL, Finkelstein A, Prasad A, Gibson J, Hui P, Theoharis CG, Carling T, Roman SA, Sosa JA, Udelsman R, Prasad ML.
BRAF(V600E) mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation.
Mod Pathol. 2012 Aug 24.

Zhu R, Seow HA, Baumann RP, Ishiguro K, Penketh PG, Shyam K, Sartorelli AC.
Design of a hypoxia-activated prodrug inhibitor of O(6)-alkylguanine-DNA alkyltransferase.
Bioorg Med Chem Lett. 2012 Aug 10.

Silasi M, Mor G.
Decidual Stromal Cells as Regulators of T-Cell Access to the Maternal-Fetal Interface.
Am J Reprod Immunol. 2012 Aug 31.

Sullivan MC, Yeo H, Roman SA, Bell RH Jr, Sosa JA.
Striving for Work-Life Balance: Effect of Marriage and Children on the Experience of 4402 US General Surgery Residents.
Ann Surg. 2012 Sep 7.

Ratner ES, Sartorelli AC, Lin ZP.
Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
Curr Opin Oncol. 2012 Jun 30.

Morgensztern D, Herbst RS.
Multitargeted Tyrosine Kinase Inhibitors in Unselected Patients With Advanced Non-Small-Cell LungCancer (NSCLC): Impressions From MONET (the Motesanib NSCLC Efficacy and Tolerability Study).
J Clin Oncol. 2012 Jul 2

Lacy J, Saadati H, Yu JB.
Complications of brain tumors and their treatment.
Hematol Oncol Clin North Am. 2012 Aug;26(4):779-96.

Park J, Wrzesinski SH, Stern E, Look M, Criscione J, Ragheb R, Jay SM, Demento SL, Agawu A, Licona Limon P, Ferrandino AF, Gonzalez D, Habermann A, Flavell RA, Fahmy TM.
Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy.
Nat Mater. 2012 Jul 15.

Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N, Abu-Khalaf M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
Br J Cancer. 2012 Apr 24;106(9):1543-50.

Penketh PG, Shyam K, Baumann RP, Ishiguro K, Patridge EV, Zhu R, Sartorelli AC.
A strategy for selective O(6) -alkylguanine-DNA alkyltransferase depletion under hypoxic conditions.
Chem Biol Drug Des. 2012 May 3.

Guest Editor: Maysa Abu-Khalaf
Authors: Erin Hofstatter, Tish Knobf, Kerry Russell, Raymond Russell.
Current Cardiology Reviews: Volume 7, Number 4

Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M.
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study.
J Clin Oncol. 2012 Apr 30.

Wong EY, Rose MG.
Why does my patient have thrombocytopenia?
Hematol Oncol Clin North Am. 2012 Apr;26(2):231-52.

Buckley DL, Van Molle I, Gareiss PC, Tae HS, Michel J, Noblin DJ, Jorgensen WL, Ciulli A, Crews CM.
Targeting the von Hippel-Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction.
J Am Chem Soc. 2012 Feb 27.

Jilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL.
CD70 expression patterns in renal cell carcinoma.
Hum Pathol. 2012 Mar 6.

Li J, Lee JJ, Chu E, Baehring JM.
Reversible Leukoencephalopathy With Stroke-Like Presentation in a Patient With 5-Dihydropyrimidine Dehydrogenase Deficiency Treated With Continuous 5-Fluorouracil Infusion.

Clin Colorectal Cancer. 2012 Mar 10.

Finkelstein A, Levy GH, Hui P, Prasad A, Virk R, Chhieng DC, Carling T, Roman SA, Sosa JA, Udelsman R, Theoharis CG, Prasad ML.
Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct.
Histopathology. 2012 Feb 15.

Yin G, Alvero AB, Craveiro V, Holmberg JC, Fu HH, Montagna MK, Yang Y, Chefetz-Menaker I, Nuti S, Rossi M, Silasi DA, Rutherford T, Mor G.
Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential.
Oncogene. 2012 Feb 20.

Koo PJ, Morgensztern D, Boyer JL, Herbst RS.
Targeting Vascular Endothelial Growth Factor in Patients With Squamous Cell Lung Cancer.
J Clin Oncol. 2012 Feb 21.

Carling T, Carty SE, Ciarleglio MM, Cooper DS, Doherty GM, Kim LT, Kloos RT, Mazzaferri EL Sr, Peduzzi PN, Roman SA, Sippel RS, Sosa JA, Stack BC Jr, Steward DL, Tufano RP, Tuttle RM, Udelsman R.
American Thyroid Association Design and Feasibility of a Prospective Randomized Controlled Trial of Prophylactic Central Lymph Node Dissection for Papillary Thyroid Carcinoma.
Thyroid. 2012 Feb 7.

Politi K, Lynch TJ.
Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.
Clin Cancer Res. 2012 Feb 8.

Nelson WK, Formica RN Jr, Cooper DL, Schwartz PE, Rutherford TJ.
An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers.
J Oncol Pharm Pract. 2012 Feb 13.

Baehring JM.
Glioblastoma multiforme-new approaches to therapy.
Cancer J. 2012 Jan;18(1):11.

Moliterno JA, Patel TR, Piepmeier JM.
Neurosurgical approach.
Cancer J. 2012 Jan;18(1):20-5.

Deshpande H, Marler V, Sosa JA.
Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer.
Onco Targets Ther. 2011;4:209-15.

Kazaure HS, Roman SA, Sosa JA.
Insular thyroid cancer: A population-level analysis of patient characteristics and predictors of survival.
Cancer. 2012 Jan 17.

Zhou J, Atsina KB, Himes BT, Strohbehn GW, Saltzman WM.
Novel delivery strategies for glioblastoma.
Cancer J. 2012 Jan;18(1):89-99.

Vest MT, Tanoue L, Soulos PR, Kim AW, Detterbeck F, Morgensztern D, Gross CP.
Thoroughness of mediastinal staging in stage IIIA non-small cell lung cancer.
J Thorac Oncol. 2012 Jan;7(1):188-95.

DeVita VT Jr.
Opinion: a personal note--40 years after the signing of the Cancer Act.
Nat Rev Clin Oncol. 2011 Nov 1;8(12):693-4.

Decker RH, Lynch TJ.
Unmet Challenges in the Use of Novel Agents in Locally Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol. 2012 Jan 23.

Marti JL, Clark VE, Harper H, Chhieng DC, Sosa JA, Roman SA.
Optimal Surgical Management of Well-Differentiated Thyroid Cancer Arising in Struma Ovarii: A Series of 4 Patients and a Review of 53 Reported Cases.
Thyroid. 2011 Dec 19.

Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, Betti M, Todeschini P, Gasparrini S, Ratner E, Silasi DA, Azodi M, Schwartz P, Rutherford TJ, Buza N, Pecorelli S, Santin AD.
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody.
J Exp Clin Cancer Res. 2011 Nov 10;30:106.

Zhou J, Liu J, Cheng CJ, Patel TR, Weller CE, Piepmeier JM, Jiang Z, Saltzman WM.
Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery.
Nat Mater. 2011 Dec 4.

Theoharis C, Roman S, Sosa JA.
The molecular diagnosis and management of thyroid neoplasms.
Curr Opin Oncol. 2011 Nov 24.

Vest MT, Tanoue L, Soulos PR, Kim AW, Detterbeck F, Morgensztern D, Gross CP.
Thoroughness of Mediastinal Staging in Stage IIIA Non-small Cell Lung Cancer.
J Thorac Oncol. 2011 Nov 30.

Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Oncogene. 2011 Dec 5.

Moran MS, Yang Q, Goyal S, Harris L, Chung G, Haffty BG.
Evaluation of vascular endothelial growth factor as a prognostic marker for local relapse in early-stage breast cancer patients treated with breast-conserving therapy.
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1236-43.

Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM.
Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors.
Biomaterials. 2011 Oct 18.

Kazaure HS, Roman SA, Sosa JA.
Medullary thyroid microcarcinoma: A population-level analysis of 310 patients
Cancer. 2011 Jun 29.

Sullivan MC, Roman SA, Sosa JA.
Does Chemotherapy Prior to Emergency Surgery Affect Patient Outcomes? Examination of 1912 Patients
Ann Surg Oncol. 2011 Jul 15.

Hanlon, D.J., Aldo, P.B., Devine, L., Alvero, A.B., Engberg, A.K., Edelson, R., Mor, G.
Enhanced Stimulation of Anti-Ovarian Cancer CD8+ T Cells by Dendritic Cells Loaded with Nanoparticle Encapsulated Tumor Antigen
(2011) American Journal of Reproductive Immunology, 65 (6), pp. 597-609.

Kluger, H.M., Dudek, A.Z., McCann, C., Ritacco, J., Southard, N., Jilaveanu, L.B., Molinaro, A., Sznol, M.
A phase 2 trial of dasatinib in advanced melanoma
(2011) Cancer, 117 (10), pp. 2202-2208. Cited 1 time.

Kluger, H.M., Hoyt, K., Bacchiocchi, A., Mayer, T., Kirsch, J., Kluger, Y., Sznol, M., Ariyan, S., Molinaro, A., Halaban, R.
Plasma markers for identifying patients with metastatic melanoma
(2011) Clinical Cancer Research, 17 (8), pp. 2417-2425.

Leizer, A.L., Alvero, A.B., Fu, H.H., Holmberg, J.C., Cheng, Y.-C., Silasi, D.-A., Rutherford, T., Mor, G.
Regulation of Inflammation by the NF-κB Pathway in Ovarian Cancer Stem Cells
(2011) American Journal of Reproductive Immunology, 65 (4), pp. 438-447.

Jeganathan, R., McGuigan, J., Campbell, F., Lynch, T.
Does pre-operative estimation of oesophageal tumour metabolic length using 18F-fluorodeoxyglucose PET/CT images compare with surgical pathology length?
(2011) European Journal of Nuclear Medicine and Molecular Imaging, 38 (4), pp. 656-662.

Govindan, R., Morgensztern, D., Kommor, M.D., Herbst, R.S., Schaefer, P., Gandhi, J., Saito, K., Zergebel, C., Schiller, J.
Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer
(2011) Journal of Thoracic Oncology, 6 (4), pp. 790-795.

Cascone, T., Herynk, M.H., Xu, L., Du, Z., Kadara, H., Nilsson, M.B., Oborn, C.J., Park, Y.-Y., Erez, B., Jacoby, J.J., Lee, J.-S., Lin, H.Y., Ciardiello, F., Herbst, R.S., Langley, R.R., Heymach, J.V.
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma
(2011) Journal of Clinical Investigation, 121 (4), pp. 1313-1328. Cited 1 time

Sequist, L.V., Waltman, B.A., Dias-Santagata, D., Digumarthy, S., Turke, A.B., Fidias, P., Bergethon, K., Shaw, A.T., Gettinger, S., Cosper, A.K., Akhavanfard, S., Heist, R.S., Temel, J., Christensen, J.G., Wain, J.C., Lynch, T.J., Vernovsky, K., Mark, E.J., Lanuti, M., Iafrate, A.J., Mino-Kenudson, M., Engelman, J.A.
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
(2011) Science Translational Medicine, 3 (75), art. no. 75ra26, .

Wistuba, I.I., Gelovani, J.G., Jacoby, J.J., Davis, S.E., Herbst, R.S.
Methodological and practical challenges for personalized cancer therapies
(2011) Nature Reviews Clinical Oncology, 8 (3), pp. 135-141. Cited 1 time.

Zhu, C.S., Pinsky, P.F., Cramer, D.W., Ransohoff, D.F., Hartge, P., Pfeiffer, R.M., Urban, N., Mor, G., Bast Jr., R.C., Moore, L.E., Lokshin, A.E., McIntosh, M.W., Skates, S.J., Vitonis, A., Zhang, Z., Ward, D.C., Symanowski, J.T., Lomakin, A., Fung, E.T., Sluss, P.M., Scholler, N., Lu, K.H., Marrangoni, A.M., Patriotis, C., Srivastava, S., Buys, S.S., Berg, C.D.
A framework for evaluating biomarkers for early detection: Validation of biomarker panels for ovarian cancer
(2011) Cancer Prevention Research, 4 (3), pp. 375-383. Cited 4 times.

Cramer, D.W., Bast Jr., R.C., Berg, C.D., Diamandis, E.P., Godwin, A.K., Hartge, P., Lokshin, A.E., Lu, K.H., McIntosh, M.W., Mor, G., Patriotis, C., Pinsky, P.F., Thornquist, M.D., Scholler, N., Skates, S.J., Sluss, P.M., Srivastava, S., Ward, D.C., Zhang, Z., Zhu, C.S., Urban, N.
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens
(2011) Cancer Prevention Research, 4 (3), pp. 365-374. Cited 4 times.

Wang, T.S., Roman, S.A., Sosa, J.A.
Differentiated thyroid cancer: An update
(2011) Current Opinion in Oncology, 23 (1), pp. 7-12.

Shah, M., Bhoumik, A., Goel, V., Dewing, A., Breitwieser, W., Kluger, H., Krajewski, S., Krajewska, M., Dehart, J., Lau, E., Kallenberg, D.M., Jeong, H., Eroshkin, A., Bennett, D.C., Chin, L., Bosenberg, M., Jones, N., Ronai, Z.A.
A role for ATF2 in regulating MITF and melanoma development.
(2010) PLoS genetics, 6 (12),

Richter, C.E., Cocco, E., Bellone, S., Silasi, D.A., Rüttinger, D., Azodi, M., Schwartz, P.E., Rutherford, T.J., Pecorelli, S., Santin, A.D.
High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
(2010) American journal of obstetrics and gynecology, 203 (6), pp. 582.e1-7.

Sequist, L.V., Gettinger, S., Senzer, N.N., Martins, R.G., Jänne, P.A., Lilenbaum, R., Gray, J.E., Iafrate, A.J., Katayama, R., Hafeez, N., Sweeney, J., Walker, J.R., Fritz, C., Ross, R.W., Grayzel, D., Engelman, J.A., Borger, D.R., Paez, G., Natale, R.
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer
(2010) Journal of Clinical Oncology, 28 (33), pp. 4953-4960. Cited 3 times.